1-9 of 9
Kanak Raina
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Yimin Qian, Kanak Raina, Kimal Rajapakshe, Dimuthu Perera, Cristian Coarfa, Tapan M. Kadia, Joseph D. Khoury, Dyana T. Saenz, David N. Saenz, Anuradha Illendula, Koichi Takahashi, Steven M. Kornblau, Michael R. Green, Andrew P. Futreal, John H. Bushweller, Craig M. Crews, Kapil N. Bhalla
Journal: Blood
Blood (2019) 134 (1): 59–73.
https://doi.org/10.1182/blood.2018893982
Published: 2019
Includes: Supplemental data
Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 890.
https://doi.org/10.1182/blood-2018-99-115692
Published: 2018
Journal Articles

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, BSc,PhD, Kanak Raina, PhD, Yimin Qian, PhD, Andrew Crew, Dyana T. Saenz, PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, David N Saenz, Craig M Crews, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1265.
https://doi.org/10.1182/blood.V130.Suppl_1.1265.1265
Published: 2017
Journal Articles

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, Yimin Qian, PhD, Kanak Raina, PhD, David N Saenz, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1239.
https://doi.org/10.1182/blood.V130.Suppl_1.1239.1239
Published: 2017
Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL

Sujan Piya, PhD, Hong Mu, MD PhD, Seemana Bhattacharya, PhD, Teresa McQueen, MS, Richard E Davis, BSPharm, MS, Vivian Ruvolo, PhD, Natalia Baran, PhD MD, Yimin Qian, PhD, Kanak Raina, PhD, Craig M Crews, PhD, M. James You, MD PhD, Patrick Zweider McKay, MDPhD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 716.
https://doi.org/10.1182/blood.V130.Suppl_1.716.716
Published: 2017
Journal Articles

Targeted Therapy for AML Expressing RUNX1 Mutation

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MDMSc, Yimin Qian, PhD, Kanak Raina, PhD, Koichi Takahashi, MD, Tapan Kadia, MD, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2472.
https://doi.org/10.1182/blood.V130.Suppl_1.2472.2472
Published: 2017
Journal Articles

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Liang Zhang, MD PhD, Kanak Raina, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Dyana T Saenz, PhD, Christopher P Mill, PhD, Michael Wang, MD, Craig Crews, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2016) 128 (22): 1058.
https://doi.org/10.1182/blood.V128.22.1058.1058
Published: 2016
Journal Articles

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T Saenz, PhD, Warren Fiskus, PhD, Kanak Raina, PhD, Taghi Manshouri, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Christopher P Mill, PhD, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig Crews, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2016) 128 (22): 747.
https://doi.org/10.1182/blood.V128.22.747.747
Published: 2016
Journal Articles

BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL

Jing Lu, PhD, Yimin Qian, PhD, Kanak Raina, PhD, Martha Altieri, MS, Hanqing Dong, PhD, Jing Wang, PhD, Xin Chen, PhD, Andrew Crew, PhD, Kevin Coleman, PhD, Craig Crews, PhD, James Winkler, PhD
Journal: Blood
Blood (2015) 126 (23): 2050.
https://doi.org/10.1182/blood.V126.23.2050.2050
Published: 2015